Health Enhancement Products, Inc. Contracts Battelle in a Final Drive to Develop Dietary Supplement and Pharmaceutical Market Programs

SCOTTSDALE, AZ--(Marketwire - May 31, 2011) - Health Enhancement Products, Inc. (OTCBB: HEPI) has executed the first phase of a multi-phase R&D contract with Columbus, Ohio-based Battelle to refine, analyze and potentially synthesize the active molecules derived from its proprietary algal extracts. These active molecules were the focus of the Company's most recent formal patent application, submitted to the USPTO several weeks ago, and are believed to be responsible for the reduction in LDL cholesterol and increase in HDL cholesterol in test subjects. Over the past two years, Health Enhancement has been conducting a variety of tests, studies and analyses to fully substantiate the efficacy of the active molecules and to verify their unique method of cholesterol regulation, among other healthful properties.

One of the greatest challenges has been the isolation of the active molecules in sufficient quantity to conduct further research and development. That obstacle has been overcome in part at Oxford Biomedical Research, based in Rochester Hills, Michigan, through process refinements that the Company considers highly confidential and proprietary. Those process refinements will then help guide Battelle researchers as they scale up the volume of the active molecules to be extracted from the test samples.

Armed with that information, Health Enhancement principals can more precisely address the nutraceutical and dietary supplement markets with targeted applications for its naturally-derived bioactive extracts.

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of algal-based products that can be used as dietary supplements and food additives. The Company's portfolio of cultures and production processes has generated bioactive products for focused health applications.

About Battelle

As the world's largest independent research and development organization, Battelle provides innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management; National Security; Health and Life Sciences; and Energy, Environment and Material Sciences. It advances scientific discovery and application by conducting $6.5 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 22,000 employees in more than 130 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security and a nuclear energy lab in the United Kingdom.

Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science, technology, engineering and mathematics (STEM) education.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit http://www.heponline.com.